Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations

6 participants · First posted Jul 23, 2025

Assessment of Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Disorders of Consciousness

10 participants · First posted Jul 9, 2026

Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)

20 participants · First posted Jul 15, 2026

CTx FUS

TTR gene editing therapy (Trucode Gene)

CYBB gene editing therapy (Trucode Gene)

JIUYUAN GENE

Triple-Gene LLC

United States

MOMOTARO-GENE INC.

Japan

Ractigen's RAG-21 Receives FDA Orphan Drug Designation for FUS-ALS Treatment

Ionis and Otsuka report Phase 3 FUSION win for ulefnersen in FUS-ALS

Ulefnersen Shows Unprecedented Recovery in Young Patients with Rare FUS-ALS